Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors

DOI: 10.1080/2162402X.2015.1065370

Keywords: Apo2L/TRAIL, EGFR, HER2, monoclonal anti-body, PARP, VEGF

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text